Navigation Links
Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
Date:12/11/2008

to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data support that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control. (vi, vii)

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control, low incidence of hypoglycemia when used with metformin or a thiazolidinedione, and progressive weight loss. BYETTA was approved in April 2005 and has been used by approximately one million patients since its introduction. For full prescribing information, visit www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used wit
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
2. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
3. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
4. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
5. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
6. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
7. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
8. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
9. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
10. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global ... Depository Trust Company (DTC) has made their final ... Chill on the Company,s stock effective December 15, ... common stock for depository and book entry transfer ... Company is now once again fully "DTC Eligible", ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Inc. (NYSE: LDR ), a recognized leader ... and high quality medical consumable accessories, today reported financial results ... Fiscal 2012 Second Quarter Highlights ... prior year period. , Gross profit grew 11 percent ...
... Inc. (NASDAQ: UPI ), a medical device ... for the treatment of voiding dysfunctions, announced today that ... President and CFO, will present the Company,s business strategy ... JMP Securities Research Conference at 12:30 pm PT on Monday, ...
Cached Medicine Technology:Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 12Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 13Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 14Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 15Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 16Landauer, Inc. Reports Fiscal 2012 Second Quarter Results 17Uroplasty to Present at the 11th Annual JMP Securities Research Conference 2
(Date:12/21/2014)... 21, 2014 Over the past 39 ... in hundreds of emergency departments across the nation, from ... have been translated into an innovative suite of tools, ... deficiencies and enhance the patient experience. , NES ... staffing and management services for hospitals, announced the development ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... and blood clots from using testosterone products such as ... shows that the male hormone testosterone may increase the ... published in the Proceedings of the National Academy of ... group of male rats with naturally occurring colon cancer. ...
(Date:12/21/2014)... 21, 2014 Concept Plus, LLC. a ... headquartered in Fairfax, VA., today announced it has been ... 50 list, which ranks the fastest growing government contracting small ... to 2013. , This is the first year that Concept ... # 20 with a 95.92% compound annual growth rate. “For ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, ... The business has drastically cut prices to all its ... until Jan. 30, 2015. Many of the hottest styles ... dresses, lace dresses, and more. , A spokesman for ... day. Whether A-line princess prom dresses or sweetheart chiffon ...
(Date:12/20/2014)... company LunaDress has recently announced its 2015 collection ... discounts on all of its special occasion dresses & wedding ... perfect wedding gown. If you have no idea of what ... Many different wedding dress styles and our dress experts are ... the current special offer, up to 80% off," the CEO ...
Breaking Medicine News(10 mins):Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2
... whom have multiple chronic illnesses face severe difficulty ... avert pending cuts to Medicare payments, according to first-hand ... today by the 125,000-member American College of Physicians (ACP). ... access-to-care were evident from the responses of almost 2000 ...
... from Hospitals Across the Country Gather to Discuss, Interactive Patient ... ... Patient Experience, WASHINGTON, April ... Care (IPC) solutions, today,announced the kick-off of GetConnected2008. Designed exclusively ...
... SAN LEANDRO, Calif., April 7, 2008 A,tiny lightstick ... percent of,all fatalities from oral cancer, according to the ... a dental group which,recommends that all adults ask their ... screening procedure with this product will become,as widespread as ...
... Day on April 25th, Suracell Inc. urges Americans to use ... their genes to promote healthy aging, SOUTH ORANGE, ... up on everything touted as "good for you?" Convinced,there,s nothing you can ... pioneer in personal genetic health. With National DNA,Day on April 25, Suracell ...
... partnership between industry and academia has led to human ... class of blood diseases called myeloproliferative disorders (MPD), which ... can evolve into leukemia. In just one year, ... of California, San Diego, Dana-Farber Cancer Institute, the Mayo ...
... Symposium and Congress, (April 7, 2008) The American ... that it will participate in a post-LASIK quality of ... which includes the U.S. Food and Drug Administration (FDA), ... Academy of Ophthalmology. ASCRS also announced that the ...
Cached Medicine News:Health News:ACP reports on how scheduled Medicare pay cuts will affect patients 2Health News:ACP reports on how scheduled Medicare pay cuts will affect patients 3Health News:GetWellNetwork Kicks Off GetConnected2008, First Annual Users Conference 2Health News:GetWellNetwork Kicks Off GetConnected2008, First Annual Users Conference 3Health News:New ViziLite Plus Could Reduce Oral Cancer Fatalities Predicts East Bay's Creative Dimensions in Dentistry 2Health News:Know Your Personal Genetic Health to Age Better Now! 2Health News:Stem cell research leads to potential new therapy for rare blood disorder 2Health News:Stem cell research leads to potential new therapy for rare blood disorder 3Health News:ASCRS to participate in and co-fund study on post-lasik quality of life with US FDA 2Health News:ASCRS to participate in and co-fund study on post-lasik quality of life with US FDA 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: